Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H8O6.C3H7N3O2 |
| Molecular Weight | 293.2307 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NCC(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
InChI
InChIKey=ICUMYBNRZRDLQO-RXSVEWSESA-N
InChI=1S/C6H8O6.C3H7N3O2/c7-1-2(8)5-3(9)4(10)6(11)12-5;4-3(5)6-1-2(7)8/h2,5,7-10H,1H2;1H2,(H,7,8)(H4,4,5,6)/t2-,5+;/m0./s1
| Molecular Formula | C3H7N3O2 |
| Molecular Weight | 117.1066 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H8O6 |
| Molecular Weight | 176.1241 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
151.3 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25622538/ |
2.4 g single, oral dose: 2.4 g route of administration: Oral experiment type: SINGLE co-administered: |
GLYCOCYAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
531.4 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25622538/ |
2.4 g single, oral dose: 2.4 g route of administration: Oral experiment type: SINGLE co-administered: |
GLYCOCYAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.74 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25622538/ |
2.4 g single, oral dose: 2.4 g route of administration: Oral experiment type: SINGLE co-administered: |
GLYCOCYAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
4.8 g 1 times / day multiple, oral Highest studied dose Dose: 4.8 g, 1 times / day Route: oral Route: multiple Dose: 4.8 g, 1 times / day Sources: |
healthy, mean age 22.5 years Health Status: healthy Age Group: mean age 22.5 years Sex: M+F Sources: |
|
2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
Other AEs: Nausea, Stomach burning sensation of... Other AEs: Nausea (grade 1, 22.2%) Sources: Stomach burning sensation of (11.1%) Hyperhomocysteinaemia (55.6%) Creatinine serum increased (33.3%) AST increased (11.1%) ALT increased (11.1%) Creatine kinase increased (11.1%) |
3 g 1 times / day multiple, oral Studied dose Dose: 3 g, 1 times / day Route: oral Route: multiple Dose: 3 g, 1 times / day Sources: |
healthy, mean age 24.3 years Health Status: healthy Age Group: mean age 24.3 years Sex: M Sources: |
Other AEs: Blood homocysteine increased... Other AEs: Blood homocysteine increased (grade 1) Sources: |
48 mg/kg 1 times / day multiple, oral Studied dose Dose: 48 mg/kg, 1 times / day Route: oral Route: multiple Dose: 48 mg/kg, 1 times / day Sources: |
healthy, mean age 24.8 years Health Status: healthy Age Group: mean age 24.8 years Sex: M Sources: |
Other AEs: Stomach pain, Bloating... Other AEs: Stomach pain Sources: Bloating Constipation (grade 2) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| ALT increased | 11.1% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| AST increased | 11.1% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| Creatine kinase increased | 11.1% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| Stomach burning sensation of | 11.1% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| Creatinine serum increased | 33.3% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| Hyperhomocysteinaemia | 55.6% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| Nausea | grade 1, 22.2% | 2.4 g 1 times / day multiple, oral Studied dose Dose: 2.4 g, 1 times / day Route: oral Route: multiple Dose: 2.4 g, 1 times / day Sources: |
healthy, mean age 23.7 years Health Status: healthy Age Group: mean age 23.7 years Sex: M+F Sources: |
| Blood homocysteine increased | grade 1 | 3 g 1 times / day multiple, oral Studied dose Dose: 3 g, 1 times / day Route: oral Route: multiple Dose: 3 g, 1 times / day Sources: |
healthy, mean age 24.3 years Health Status: healthy Age Group: mean age 24.3 years Sex: M Sources: |
| Bloating | 48 mg/kg 1 times / day multiple, oral Studied dose Dose: 48 mg/kg, 1 times / day Route: oral Route: multiple Dose: 48 mg/kg, 1 times / day Sources: |
healthy, mean age 24.8 years Health Status: healthy Age Group: mean age 24.8 years Sex: M Sources: |
|
| Stomach pain | 48 mg/kg 1 times / day multiple, oral Studied dose Dose: 48 mg/kg, 1 times / day Route: oral Route: multiple Dose: 48 mg/kg, 1 times / day Sources: |
healthy, mean age 24.8 years Health Status: healthy Age Group: mean age 24.8 years Sex: M Sources: |
|
| Constipation | grade 2 | 48 mg/kg 1 times / day multiple, oral Studied dose Dose: 48 mg/kg, 1 times / day Route: oral Route: multiple Dose: 48 mg/kg, 1 times / day Sources: |
healthy, mean age 24.8 years Health Status: healthy Age Group: mean age 24.8 years Sex: M Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. | 2008-09 |
|
| Successful treatment of a guanidinoacetate methyltransferase deficient patient: findings with relevance to treatment strategy and pathophysiology. | 2007-07 |
|
| Guanidinoacetate inhibits glutamate uptake in rat striatum of rats at different ages. | 2007-06 |
|
| Evidence that the inhibitory effects of guanidinoacetate on the activities of the respiratory chain, Na+,K+-ATPase and creatine kinase can be differentially prevented by taurine and vitamins E and C administration in rat striatum in vivo. | 2007-05 |
|
| A prevalent pathogenic GAMT mutation (c.59G>C) in Portugal. | 2007-05 |
|
| [Cerebral creatine transporter deficiency: an infradiagnosed neurometabolic disease]. | 2007-03-27 |
|
| Treatment monitoring of brain creatine deficiency syndromes: a 1H- and 31P-MR spectroscopy study. | 2007-03 |
|
| Supervised group Lasso with applications to microarray data analysis. | 2007-02-22 |
|
| Reactome: a knowledge base of biologic pathways and processes. | 2007 |
|
| Overexpression of GAMT restores GAMT activity in primary GAMT-deficient fibroblasts. | 2006-12 |
|
| Reduced intestinal and renal amino acid transport in PDK1 hypomorphic mice. | 2006-11 |
|
| Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. | 2006-11 |
|
| High cerebral guanidinoacetate and variable creatine concentrations in argininosuccinate synthetase and lyase deficiency: implications for treatment? | 2006-11 |
|
| Methods for the diagnosis of creatine deficiency syndromes: a comparative study. | 2006-09-30 |
|
| Anisoin: a useful pre-chromatographic derivatization fluorogenic reagent for LC analysis of guanidino compounds. | 2006-09-11 |
|
| [Diagnosis and treatment of brain creatine deficiency syndromes]. | 2006-08-31 |
|
| Presymptomatic treatment of neonatal guanidinoacetate methyltransferase deficiency. | 2006-08-22 |
|
| GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. | 2006-08-08 |
|
| S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. | 2006-08 |
|
| Biochemical validation of a rat model for polycystic kidney disease: comparison of guanidino compound profile with the human condition. | 2006-06 |
|
| Cerebral 1H MR spectroscopy showing elevation of brain guanidinoacetate in argininosuccinate lyase deficiency. | 2006-05 |
|
| Prenatal diagnosis of guanidinoacetate methyltransferase deficiency: increased guanidinoacetate concentrations in amniotic fluid. | 2006-04 |
|
| Increased guanidino species in murine and human succinate semialdehyde dehydrogenase (SSADH) deficiency. | 2006-04 |
|
| Intrastriatal administration of guanidinoacetate inhibits Na+, K+-ATPase and creatine kinase activities in rat striatum. | 2006-03 |
|
| Assay for the simultaneous determination of guanidinoacetic acid, creatinine and creatine in plasma and urine by capillary electrophoresis UV-detection. | 2006-03 |
|
| Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. | 2006-03 |
|
| Metabolic phenotyping of nude and normal (Alpk:ApfCD, C57BL10J) mice. | 2006-02 |
|
| Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry. | 2006-02 |
|
| Theoretical study of the methyl transfer in guanidinoacetate methyltransferase. | 2006-01-12 |
|
| A mutation on exon 6 of guanidinoacetate methyltransferase (GAMT) gene supports a different function for isoform a and b of GAMT enzyme. | 2006-01 |
|
| Urinary excretion of guanidinoacetic acid in rats with diabetic nephropathy. | 2006 |
|
| Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study. | 2005-12-15 |
|
| Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. | 2005-12 |
|
| 1H MR spectroscopy of the brain in Cr transporter defect. | 2005-11 |
|
| Laboratory diagnosis of defects of creatine biosynthesis and transport. | 2005-11 |
|
| Phosphagen kinase of the giant tubeworm Riftia pachyptila. Cloning and expression of cytoplasmic and mitochondrial isoforms of taurocyamine kinase. | 2005-10-30 |
|
| The mimetics of antiadhesive peptides as the inhibitors of Mycobacterium kansasii phagocytosis. | 2005-09 |
|
| 1H chemical shift imaging of the brain in guanidino methyltransferase deficiency, a creatine deficiency syndrome; guanidinoacetate accumulation in the gray matter. | 2005-09 |
|
| Origin and properties of cytoplasmic and mitochondrial isoforms of taurocyamine kinase. | 2005-07 |
|
| Urinary creatinine and arsenic metabolism. | 2005-07 |
|
| Lower force and impaired performance during high-intensity electrical stimulation in skeletal muscle of GAMT-deficient knockout mice. | 2005-07 |
|
| Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. | 2005-05-26 |
|
| Use of denaturing HPLC to provide efficient detection of mutations causing guanidinoacetate methyltransferase deficiency. | 2005-05-17 |
|
| Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. | 2005-04-15 |
|
| Creatine metabolism in combined methylmalonic aciduria and homocystinuria. | 2005-04 |
|
| Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. | 2005-04 |
|
| A comprehensive update of the sequence and structure classification of kinases. | 2005-03-16 |
|
| [Creatine deficiency syndromes]. | 2005-03 |
|
| Isolation, characterization, and cDNA-derived amino acid sequence of glycocyamine kinase from the tropical marine worm Namalycastis sp. | 2005-03 |
|
| L-arginine increases plasma homocysteine in apoE-/-/iNOS-/- double knockout mice. | 2004-12 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:47 GMT 2025
by
admin
on
Mon Mar 31 17:59:47 GMT 2025
|
| Record UNII |
C29EEY275R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
54741687
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
923060-69-9
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
C29EEY275R
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
